That is the better article on CanopyCanopy Growth: Best Long Term Investment In Marijuana Feb. 15, 2017 2:25 PM TWMJF Summary Canopy Growth's y/y Q3 revenue soared 244% from $2.6 million to $7.3 million while y/y revenue for the 9 months ending 12/31 grew 227% from $5.9 million to $19.2 million. Canada's political and social situation collectively show a positive reception to legalizing marijuana , enabling a friendly environment for Canopy Growth to expand their business. Research reports indicate that annual Marijuana sales will reach between $5 billion to $8 billion by 2021, assuming legalization takes place. Just the Beginning Canopy Growth (OTCPK: OTCPK:TWMJF), previously known as Tweed, has emerged as the dominant medical marijuana supplier in Canada. The stock is up over 350% in the past year from $2 to a little above $9 currently. Canopy Growth recently changed its TSX ticker to WEED and announced its acquisition of Mettrum Health Corp (TSXV: MT). Earlier today, the cannabis giant reported its Q3 2017 financials which saw the company posting significant y/y growth on the top line as well as completing a key acquisition in Mettrum Health. Canopy's y/y Q3 revenue is up 244% from $2.6 million in 2016 to $7.3 million in 2017. For the 9 months ending 12/31, y/y revenue is up an astonishing 227% from $5.9 million to $19.2 million. Despite the healthy growth and great fiscal year thus far, the stock tanked 8% today following the earnings report. We believe this dip, which was expected by those who follow the stock closely, opens up a nice buying opportunity for long term investors who are looking to invest in an industry with massive upside in the next half decade.